South Korea
· Delayed Price · Currency is KRW Medy-Tox Statistics
Total Valuation
Medy-Tox has a market cap or net worth of KRW 851.45 billion. The enterprise value is 876.84 billion.
| Market Cap | 851.45B |
| Enterprise Value | 876.84B |
Important Dates
The last earnings date was Tuesday, August 12, 2025.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | Sep 27, 2024 |
Share Statistics
Medy-Tox has 7.02 million shares outstanding. The number of shares has increased by 36.62% in one year.
| Current Share Class | 7.02M |
| Shares Outstanding | 7.02M |
| Shares Change (YoY) | +36.62% |
| Shares Change (QoQ) | +72.65% |
| Owned by Insiders (%) | 19.19% |
| Owned by Institutions (%) | 12.93% |
| Float | 5.23M |
Valuation Ratios
The trailing PE ratio is 45.31 and the forward PE ratio is 20.66.
| PE Ratio | 45.31 |
| Forward PE | 20.66 |
| PS Ratio | 3.58 |
| PB Ratio | 1.83 |
| P/TBV Ratio | 1.90 |
| P/FCF Ratio | 27.92 |
| P/OCF Ratio | 20.81 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.54, with an EV/FCF ratio of 28.76.
| EV / Earnings | 41.25 |
| EV / Sales | 3.68 |
| EV / EBITDA | 16.54 |
| EV / EBIT | 26.62 |
| EV / FCF | 28.76 |
Financial Position
The company has a current ratio of 1.57, with a Debt / Equity ratio of 0.16.
| Current Ratio | 1.57 |
| Quick Ratio | 0.99 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | 1.64 |
| Debt / FCF | 2.51 |
| Interest Coverage | 15.49 |
Financial Efficiency
Return on equity (ROE) is 4.35% and return on invested capital (ROIC) is 2.99%.
| Return on Equity (ROE) | 4.35% |
| Return on Assets (ROA) | 2.70% |
| Return on Invested Capital (ROIC) | 2.99% |
| Return on Capital Employed (ROCE) | 5.45% |
| Revenue Per Employee | 328.72M |
| Profits Per Employee | 29.36M |
| Employee Count | 724 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 1.57 |
Taxes
In the past 12 months, Medy-Tox has paid 2.24 billion in taxes.
| Income Tax | 2.24B |
| Effective Tax Rate | 9.68% |
Stock Price Statistics
The stock price has decreased by -33.75% in the last 52 weeks. The beta is 0.39, so Medy-Tox's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | -33.75% |
| 50-Day Moving Average | 157,728.00 |
| 200-Day Moving Average | 144,757.50 |
| Relative Strength Index (RSI) | 22.19 |
| Average Volume (20 Days) | 59,680 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medy-Tox had revenue of KRW 237.99 billion and earned 21.25 billion in profits. Earnings per share was 2,677.00.
| Revenue | 237.99B |
| Gross Profit | 143.53B |
| Operating Income | 26.76B |
| Pretax Income | 23.12B |
| Net Income | 21.25B |
| EBITDA | 46.85B |
| EBIT | 26.76B |
| Earnings Per Share (EPS) | 2,677.00 |
Balance Sheet
The company has 54.49 billion in cash and 76.62 billion in debt, giving a net cash position of -22.13 billion or -3,152.34 per share.
| Cash & Cash Equivalents | 54.49B |
| Total Debt | 76.62B |
| Net Cash | -22.13B |
| Net Cash Per Share | -3,152.34 |
| Equity (Book Value) | 464.65B |
| Book Value Per Share | 65,730.60 |
| Working Capital | 63.70B |
Cash Flow
In the last 12 months, operating cash flow was 40.92 billion and capital expenditures -10.43 billion, giving a free cash flow of 30.49 billion.
| Operating Cash Flow | 40.92B |
| Capital Expenditures | -10.43B |
| Free Cash Flow | 30.49B |
| FCF Per Share | 4,343.84 |
Margins
Gross margin is 60.31%, with operating and profit margins of 11.24% and 9.34%.
| Gross Margin | 60.31% |
| Operating Margin | 11.24% |
| Pretax Margin | 9.71% |
| Profit Margin | 9.34% |
| EBITDA Margin | 19.68% |
| EBIT Margin | 11.24% |
| FCF Margin | 12.81% |
Dividends & Yields
This stock pays an annual dividend of 1,100.00, which amounts to a dividend yield of 0.91%.
| Dividend Per Share | 1,100.00 |
| Dividend Yield | 0.91% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 37.90% |
| Buyback Yield | -36.62% |
| Shareholder Yield | -35.72% |
| Earnings Yield | 2.50% |
| FCF Yield | 3.58% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 28, 2022. It was a forward split with a ratio of 1.05.
| Last Split Date | Dec 28, 2022 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
Medy-Tox has an Altman Z-Score of 5.96 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.96 |
| Piotroski F-Score | 6 |